Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Telmisartan Plus Hydrochlorothiazide in Subjects With Mild-to-moderate Hypertension Who Failed to Respond to Telmisartan Monotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02177500
Recruitment Status : Completed
First Posted : June 27, 2014
Last Update Posted : July 8, 2014
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
An eight week study to compare the effect of a fixed dose combination of Telmisartan 40 mg plus hydrochlorothiazide (HCTZ) 12.5 mg to Telmisartan 40 mg alone on diastolic and systolic blood pressure in patients who fail to respond adequately to telmisartan monotherapy.

Condition or disease Intervention/treatment Phase
Hypertension Drug: Telmisartan + hydrochlorothiazide Drug: Telmisartan Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 327 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: An Eight Week Randomized, Double-Blind Study Comparing a Fixed Dose Combination of Telmisartan 40 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 40 mg in Patients Who Fail to Respond Adequately to Treatment With Telmisartan 40 mg
Study Start Date : January 2000
Actual Primary Completion Date : May 2000

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Telmisartan + hydrochlorothiazide and matching placebo Drug: Telmisartan + hydrochlorothiazide
Drug: Placebo
Experimental: Telmisartan and matching placebo Drug: Telmisartan
Drug: Placebo



Primary Outcome Measures :
  1. Change from baseline in seated diastolic blood pressure (DBP) [ Time Frame: baseline and after 8 weeks of treatment ]

Secondary Outcome Measures :
  1. Change from baseline in seated systolic blood pressure (SBP) [ Time Frame: baseline and after 8 weeks of treatment ]
  2. Blood pressure control [ Time Frame: 8 weeks ]
  3. Systolic blood pressure response [ Time Frame: 8 weeks ]
  4. Incidence of adverse events [ Time Frame: up to 16 weeks ]
  5. Change from baseline in physical examination [ Time Frame: Baseline and day 56 ]
  6. Change from baseline in heart rate [ Time Frame: Baseline, day 28 and 56 ]
  7. Change from baseline in laboratory parameters [ Time Frame: Baseline and day 56 ]
  8. Change from baseline in 12-lead ECG (electrocardiogram) [ Time Frame: Baseline and day 56 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • History of mild-to-moderate hypertension
  • Patients who fail to respond adequately to telmisartan monotherapy
  • Participants between 18 and 80 years of age
  • Willingness and ability to provide written informed consent

Exclusion Criteria:

  • Patients taking more than three anti-hypertensive medications at the screening visit
  • Pre-menopausal women

    • Who are not surgically sterile
    • Who are NOT practicing acceptable means of birth control or who do NOT plan to continue using an acceptable method throughout the study. Acceptable methods of birth control include intrauterine device (IUD), oral, implantable or injectable contraceptives
  • Any women:

    • Who has a positive serum pregnancy test at screening (Visit 1) or baseline (Visit 3)
    • Who is nursing
  • Hepatic and/or renal dysfunction as defined by the following laboratory parameters

    • SGPT (serum glutamate pyruvate transaminase) or SGOT (serum glutamate oxaloacetate transaminase) greater than two times the upper limit of normal
    • Serum creatinine > 2.3 mg/dL
  • Clinically relevant sodium depletion, hyperkalemia, or hypokalemia at baseline
  • Known or suspected secondary hypertension
  • Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney; post-renal transplant patients, presence of only one functioning kidney
  • Congestive heart failure (CHF) (NYHA (New York Heart Association) functional class CHF III-IV)
  • Unstable angina within the past three months
  • Stroke within the past six months
  • Myocardial infarction or cardiac surgery within the past three months
  • PTCA (percutaneous transluminal coronary angioplasty) within the past three months
  • History of symptoms characteristic of angioedema during treatment with ACE inhibitors, angiotension II antagonists, thiazide diuretics, β-blockers or calcium channel blockers
  • Sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator
  • Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve
  • Administration of digoxin or other digitalis-type drugs
  • Patients with Type I or Type II diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an HbA1C ≥ 10%
  • Known drug or alcohol dependency within the past one year period
  • Concomitant administration of medications known to affect blood pressure, except medications allowed by the protocol
  • Patients receiving any investigational therapy within one month of signing the informed consent form. Patients who have participated in previous telmisartan (except if they were on the fixed dose combination in the 502.261 study or enrolled in the 502.321 open-label extension study) studies may participate in this study provided there has been at least one month between discontinuing the previous study and signing the consent for the present study
  • Known hypersensitivity to any component of the formulations
  • Any clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of trial medication

Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT02177500     History of Changes
Other Study ID Numbers: 502.323
First Posted: June 27, 2014    Key Record Dates
Last Update Posted: July 8, 2014
Last Verified: July 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Hydrochlorothiazide
Telmisartan, hydrochlorothiazide drug combination
Hypertension
Vascular Diseases
Cardiovascular Diseases
Telmisartan
Antihypertensive Agents
Diuretics
Natriuretic Agents
Physiological Effects of Drugs
Sodium Chloride Symporter Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists